Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Russano

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Anti-Cancer Drugs|January 14, 2020
Response to cabozantinib in renal cell carcinoma with cardiac metastasesMarco Stellato, Maria Concetta Cursano, Fabrizio Citarella, et al.
Expert Opinion on Pharmacotherapy|February 27, 2013
'Old' and 'new' drugs for the treatment of cancer painDaniele Santini, Gaetano Lanzetta, Emanuela Dell'Aquila, et al.
Journal for Immunotherapy of Cancer|June 22, 2024
Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)Michele Iuliani, Sonia Simonetti, Leonardo Cristofani, et al.
Lung Cancer (Amsterdam, Netherlands)|July 13, 2026
Germline testing in lung cancer: evidence of enrichment without a standardized selection strategy - a systematic reviewFabrizio Citarella, Roberto Ferrara, Massimo Di Maio, et al.
Recenti Progressi in Medicina|December 28, 2020
[Target therapies in translocated ALK lung cancer: treatment management in oncology center of Lazio.]Serena Ricciardi, Fabiana Cecere, Mario Rosario D'Andrea, et al.
Journal of Translational Medicine|January 17, 2026
Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non-small cell lung cancerSilvia Cavaliere, Marta Fogolari, Michele Iuliani, et al.
Expert Opinion on Biological Therapy|August 25, 2020
Denosumab for cancer-related bone lossEmanuela Dell'Aquila, Grazia Armento, Michele Iuliani, et al.
Oncotarget|March 25, 2020
Prognostic and predictive factors in pancreatic cancerEmanuela Dell'Aquila, Claudia Angela Maria Fulgenzi, Alessandro Minelli, et al.
Current Oncology (Toronto, Ont.)|February 24, 2023
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and BiomarkersMarco Russano, Giulia La Cava, Alessio Cortellini, et al.
Lung Cancer (Amsterdam, Netherlands)|April 11, 2026
A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumabRita Chiari, Marco Russano, Giacomo Leva, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Anti-Cancer Drugs|January 14, 2020
Response to cabozantinib in renal cell carcinoma with cardiac metastasesMarco Stellato, Maria Concetta Cursano, Fabrizio Citarella, et al.
Expert Opinion on Pharmacotherapy|February 27, 2013
'Old' and 'new' drugs for the treatment of cancer painDaniele Santini, Gaetano Lanzetta, Emanuela Dell'Aquila, et al.
Journal for Immunotherapy of Cancer|June 22, 2024
Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)Michele Iuliani, Sonia Simonetti, Leonardo Cristofani, et al.
Lung Cancer (Amsterdam, Netherlands)|July 13, 2026
Germline testing in lung cancer: evidence of enrichment without a standardized selection strategy - a systematic reviewFabrizio Citarella, Roberto Ferrara, Massimo Di Maio, et al.
Recenti Progressi in Medicina|December 28, 2020
[Target therapies in translocated ALK lung cancer: treatment management in oncology center of Lazio.]Serena Ricciardi, Fabiana Cecere, Mario Rosario D'Andrea, et al.
Journal of Translational Medicine|January 17, 2026
Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non-small cell lung cancerSilvia Cavaliere, Marta Fogolari, Michele Iuliani, et al.
Expert Opinion on Biological Therapy|August 25, 2020
Denosumab for cancer-related bone lossEmanuela Dell'Aquila, Grazia Armento, Michele Iuliani, et al.
Oncotarget|March 25, 2020
Prognostic and predictive factors in pancreatic cancerEmanuela Dell'Aquila, Claudia Angela Maria Fulgenzi, Alessandro Minelli, et al.
Current Oncology (Toronto, Ont.)|February 24, 2023
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and BiomarkersMarco Russano, Giulia La Cava, Alessio Cortellini, et al.
Lung Cancer (Amsterdam, Netherlands)|April 11, 2026
A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumabRita Chiari, Marco Russano, Giacomo Leva, et al.
Pageof 8